Lilly nets 'breakthrough' for CGRP Emgality by Eric Sagonowsky Thursday, November 15, 2018 The FDA has handed Lilly’s Emgality a 'breakthrough' nod in cluster headaches. Lilly plans to file for approval in that use by the end of the year.
Teva’s sunny forecast for migraine drug raises eyebrows by Arlene Weintraub Thursday, November 1, 2018 Concerns about discounting on Teva's migraine drug Ajovy are high as the company's generics unit and MS blockbuster falter.
PBM giant to cover Amgen, Lilly CGRP drugs, but shut out Teva by Eric Sagonowsky Wednesday, October 17, 2018 Allergan and Eli Lilly won coverage from PBM giant Express Scripts for their new migraine launches, but Teva's Ajovy was left out in the cold.
Was last week's Teva sell-off warranted? Depends who you ask by Carly Helfand Tuesday, October 2, 2018 Last week, investors concerned about generics trends and migraine competition cratered Teva’s shares. But did they need to worry? Analysts disagree.
